View all news

    TREMFYA® (guselkumab) Induces Clinical and Endoscopic Improvements in Patients with Moderately to Severely Active Crohn’s Disease based on Interim Results from Phase 2 Study

    10/12/2020
    Download(opens in new window)PDF 257 KB

    Multimedia Files:

    View all news
    Questions? Please contact us:
    1-800-950-5089 investor-relations@its.jnj.com